Label: INDOMETHACIN ER - indomethacin capsule 

  • NDC Code(s): 12634-160-00, 12634-160-25, 12634-160-54, 12634-160-55, view more
    12634-160-57, 12634-160-59, 12634-160-60, 12634-160-71, 12634-160-79, 12634-160-80, 12634-160-84, 12634-160-85, 12634-160-91, 12634-160-97, 12634-838-00, 12634-838-50, 12634-838-54, 12634-838-55, 12634-838-57, 12634-838-59, 12634-838-60, 12634-838-61, 12634-838-66, 12634-838-67, 12634-838-71, 12634-838-79, 12634-838-80, 12634-838-84, 12634-838-85, 12634-838-90, 12634-838-91, 12634-838-95, 12634-838-97
  • Packager: Apotheca, Inc.
  • This is a repackaged label.
  • Source NDC Code(s): 0185-0720, 10702-016
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated 04/10

If you are a consumer or patient please visit this version.

  • BOXED WARNING(What is this?)

    BOXED WARNING

    Cardiovascular Risk
    • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS).
    • Indomethacin is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNING).
    Gastrointestinal Risk
    • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS).
    Close
  • DESCRIPTION

    Indomethacin Capsules, USP for oral administration are provided in one dosage strengths which contain 75 mg of indomethacin. Indomethacin is a non-steroidal anti-inflammatory indole derivative designated chemically as 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid.

    The structural formula is:

    image of structural formula





    C19H16ClNO4       M.W. 357.79

    Manufacture KVK-Tech. Inc. Each extended release capsule contains 75 mg of Indomethacin. In addition each capsule contains the following inactive ingredients:
    corn starch, D and C yellow #10, gelatin, mannitol, povidone, sucrose, talc, and titanium dioxide.

    Manufacture Sandoz, Inc.Each extended-release capsule, for oral administration contains 75 mg of indomethacin. In addition, each capsule contains the following inactive ingredients: D and C yellow No. 10, D and C yellow No. 10 aluminum lake, FD and C blue No. 1 aluminum lake, FD and C blue No. 2 aluminum lake, FD and C red No. 40 aluminum lake, FD and C green No. 3, ethylcellulose, gelatin, lactose monohydrate, povidone, silicon dioxide, sodium lauryl sulfate, corn starch, sucrose, talc and titanium dioxide.
    This product meets USP Drug Release Test 2 Specifications.


    Close
  • CLINICAL PHARMACOLOGY

    Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) that exhibits antipyretic and analgesic properties. Its mode of action, like that of other anti-inflammatory drugs, is not known. However, its therapeutic action is not due to pituitary-adrenal stimulation.

    Indomethacin is a potent inhibitor of prostaglandin synthesis in vitro. Concentrations are reached during therapy which have been demonstrated to have an effect in vivo as well. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Moreover, prostaglandins are known to be among the mediators of inflammation. Since indomethacin is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.

    Indomethacin has been shown to be an effective anti-inflammatory agent, appropriate for long-term use in rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis.

    Indomethacin affords relief of symptoms; it does not alter the progressive course of the underlying disease.

    Indomethacin suppresses inflammation in rheumatoid arthritis as demonstrated by relief of pain, and reduction of fever, swelling and tenderness. Improvement in patients treated with indomethacin for rheumatoid arthritis has been demonstrated by a reduction in joint swelling, average number of joints involved, and morning stiffness; by increased mobility as demonstrated by a decrease in walking time; and by improved functional capability as demonstrated by an increase in grip strength. Indomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of rheumatoid arthritis. In such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adverse effects.

    Indomethacin has been reported to diminish basal and CO2 stimulated cerebral blood flow in healthy volunteers following acute oral and intravenous administration. In one study, after one week of treatment with orally administered indomethacin, this effect on basal cerebral blood flow had disappeared. The clinical significance of this effect has not been established.

    Indomethacin capsules have been found effective in relieving the pain, reducing the fever, swelling, redness, and tenderness of acute gouty arthritis (see indications and usage).

    Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours. Orally administered indomethacin capsules are virtually 100% bioavailable, with 90% of the dose absorbed within 4 hours. A single 50 mg dose of indomethacin oral suspension was found to be bioequivalent to a 50 mg indomethacin capsule when each was administered with food.

    Indomethacin is eliminated via renal excretion, metabolism, and biliary excretion. Indomethacin undergoes appreciable enterohepatic circulation. The mean half-life of indomethacin is estimated to be about 4.5 hours. With a typical therapeutic regimen of 25 mg or 50 mg t.i.d., the steady-state plasma concentrations of indomethacin are an average 1.4 times those following the first dose.

    Indomethacin exists in the plasma as the parent drug and its desmethyl, desbenzoyl, and desmethyl-desbenzoyl metabolites, all in the unconjugated form. About 60% of an oral dosage is recovered in urine as drug and metabolites (26% as indomethacin and its glucuronide), and 33% is recovered in feces (1.5% as indomethacin).

    About 99% of indomethacin is bound to protein in plasma over the expected range of therapeutic plasma concentrations. Indomethacin has been found to cross the blood-brain barrier and the placenta.

    Close
  • INDICATIONS AND USAGE

    Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS)

    Indomethacin has been found effective in active stages of the following:

    1. Moderate to severe rheumatoid arthritis including acute flares of chronic disease.
    2. Moderate to severe ankylosing spondylitis.
    3. Moderate to severe osteoarthritis.
    4. Acute painful shoulder (bursitis and/or tendinitis).
    5. Acute gouty arthritis.
    Close
  • CONTRAINDICATIONS

    Indomethacin is contraindicated in patients with known hypersensitivity to indomethacin or the excipients (see DESCRIPTION).

    Indomethacin should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic/anaphylactoid reactions to NSAIDs have been reported in such patients (see WARNINGS: Anaphylactic/Anaphylactoid Reactions, and PRECAUTIONS:General:preexisting Asthma).

    Indomethacin is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).

    Close
  • WARNINGS

    Cardiovascular Effects
    Cardiovascular Thrombotic Events

    Clinical trials of several COX-2 selective and nonselective NSAIDs of up to 3 years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.

    There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious GI events (see WARNINGS: Gastrointestinal Effects).

    Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke (see CONTRAINDICATIONS).

    Hypertension

    NSAIDs, including indomethacin, can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including indomethacin, should be used with caution in patients with hypertension. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.

    Congestive Heart Failure and Edema

    Fluid retention and edema have been observed in some patients taking NSAIDs. Indomethacin should be used with caution in patients with fluid retention or heart failure.

    In a study of patients with severe heart failure and hyponatremia, indomethacin was associated with significant deterioration of circulatory hemodynamics, presumably due to inhibition of prostaglandin dependent compensatory mechanisms.

    Gastrointestinal Effects

    Risk of Ulceration, Bleeding, and Perforation

    NSAIDs, including indomethacin, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3 to 6 months, and in about 2 to 4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.

    Rarely, in patients taking indomethacin, intestinal ulceration has been associated with stenosis and obstruction. Gastrointestinal bleeding without obvious ulcer formation and perforation of preexisting sigmoid lesions (diverticulum, carcinoma, etc.) have occurred. Increased abdominal pain in ulcerative colitis patients or the development of ulcerative colitis and regional ileitis have been reported to occur rarely.

    NSAIDs should be prescribed with extreme caution in those with a prior history of ulcer disease or gastrointestinal bleeding. Patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared to patients with neither of these risk factors. Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population.

    To minimize the potential risk for an adverse GI event in patients treated with an NSAID, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered.

    Renal Effects

    Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a non-steroidal anti-inflammatory drug may cause a dose dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate over renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, patients with volume depletion, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

    Increases in serum potassium concentration, including hyperkalemia, have been reported with use of indomethacin, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state (see PRECAUTIONS: Drug Interactions).

    Advanced Renal Disease

    No information is available from controlled clinical studies regarding the use of indomethacin in patients with advanced renal disease. Therefore, treatment with indomethacin is not recommended in these patients with advanced renal disease. If indomethacin therapy must be initiated, close monitoring of the patient's renal function is advisable.

    Advanced Renal Disease

    No information is available from controlled clinical studies regarding the use of indomethacin in patients with advanced renal disease. Therefore, treatment with indomethacin is not recommended in these patients with advanced renal disease. If indomethacin therapy must be initiated, close monitoring of the patient's renal function is advisable.

    Anaphylactic/Anaphylactoid Reactions

    As with other NSAIDs, anaphylactic/anaphylactoid reactions may occur in patients without known prior exposure to indomethacin. Indomethacin should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs (see CONTRAINDICATIONS and PRECAUTIONS: General: Preexisting Asthma). Emergency help should be sought in cases where an anaphylactic/anaphylactoid reaction occurs.

    Skin Reactions

    NSAIDs, including indomethacin, can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.

    Pregnancy

    In late pregnancy, as with other NSAIDs, indomethacin should be avoided because it may cause premature closure of the ductus arteriosus.

    Ocular Effects

    Corneal deposits and retinal disturbances, including those of the macula, have been observed in some patients who had received prolonged therapy with indomethacin. The prescribing physician should be alert to the possible association between the changes noted and indomethacin. It is advisable to discontinue therapy if such changes are observed. Blurred vision may be a significant symptom and warrants a thorough ophthalmological examination. Since these changes may be asymptomatic, ophthalmologic examination at periodic intervals is desirable in patients where therapy is prolonged.

    Central Nervous System Effects

    Indomethacin may aggravate depression or other psychiatric disturbances, epilepsy, and parkinsonism, and should be used with considerable caution in patients with these conditions. If severe CNS adverse reactions develop, indomethacin should be discontinued.

    Indomethacin may cause drowsiness; therefore, patients should be cautioned about engaging in activities requiring mental alertness and motor coordination, such as driving a car. Indomethacin may also cause headache. Headache which persists despite dosage reduction requires cessation of therapy with indomethacin.

    Close
  • PRECAUTIONS

    GENERAL

    Indomethacin cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.

    The pharmacological activity of indomethacin in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.

    Hepatic Effects

    Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs, including indomethacin. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported.

    A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test values has occured, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with indomethacin. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), indomethacin should be discontinued.

    Hematological Effects

    Anemia is sometimes seen in patients receiving NSAIDs, including indomethacin. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including indomethacin, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia.

    NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving indomethacin who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored.

    Preexisting Asthma

    Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm which can be fatal. Since cross-reactivity, including bronchospasm, between aspirin and other non-steroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, indomethacin should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma.

    INFORMATION FOR PATIENTS

    Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed.

    1. Indomethacin, like other NSAIDs, may cause serious CV side effects, such as MI or stroke, which may result in hospitalization and even death. Although serious CV events can occur without warning symptoms, patients should be alert for the signs and symptoms of chest pain, shortness of breath, weakness, slurring of speech, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up (see WARNINGS: Cardiovascular Effects).
    2. Indomethacin, like other NSAIDs, can cause GI discomfort and, rarely, serious GI side effects, such as ulcers and bleeding, which may result in hospitalization and even death. Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative signs or symptoms including epigastric pain, dyspepsia, melena, and hematemesis. Patients should be apprised of the importance of this follow-up (see WARNINGS: Gastrointestinal Effects: Risk of Ulceration, Bleeding, and Perforation).
    3. Indomethacin, like other NSAIDs, can cause serious skin side effects such as exfoliative dermatitis, SJS, and TEN, which may result in hospitalizations and even death. Although serious skin reactions may occur without warning, patients should be alert for the signs and symptoms of skin rash and blisters, fever, or other signs of hypersensitivity such as itching, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be advised to stop the drug immediately if they develop any type of rash and contact their physicians as soon as possible.
    4. Patients should promptly report signs or symptoms of unexplained weight gain or edema to their physicians.
    5. Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness and "flu-like" symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.
    6. Patients should be informed of the signs of an anaphylactic/anaphylactoid reaction (e.g. difficulty breathing, swelling of the face or throat). If these occur, patients should be instructed to seek immediate emergency help (seeWARNINGS).
    7. In late pregnancy, as with other NSAIDs, indomethacin should be avoided because it may cause premature closure of the ductus arteriosus.

    LABORATORY TESTS

    Because serious GI tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of GI bleeding. Patients on long-term treatment with NSAIDs should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (e.g., eosinophilia, rash, etc.) or if abnormal liver tests persist or worsen, indomethacin should be discontinued

    DRUG INTERACTIONS

    ACE Inhibitors and Angiotensin II Antagonists

    Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and angiotensin II antagonists. Indomethacin can reduce the antihypertensive effects of captopril and losartan. These interactions should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors or angiotensin II antagonists. In some patients with compromised renal function, the coadministration of an NSAID and an ACE inhibitor or an angiotensin II antagonist may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible.

    Aspirin

    When indomethacin is administered with aspirin, its protein binding is reduced, although the clearance of free indomethacin is not altered. The clinical significance of this interaction is not known.

    The use of indomethacin in conjunction with aspirin or other salicylates is not recommended. Controlled clinical studies have shown that the combined use of indomethacin and aspirin does not produce any greater therapeutic effect than the use of indomethacin alone. In a clinical study of the combined use of indomethacin and aspirin, the incidence of gastrointestinal side effects was significantly increased with combined therapy.

    In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.

    Beta-Adrenoceptor Blocking Agents

    Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal anti-inflammatory drugs including indomethacin has been reported. Therefore, when using these blocking agents to treat hypertension, patients should be observed carefully in order to confirm that the desired therapeutic effect has been obtained.

    Cyclosporin

    Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin. NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.

    Diflunisal

    In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin. In some patients, combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage. Therefore, diflunisal and indomethacin should not be used concomitantly.

    Digoxin

    Indomethacin given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. Therefore, when indomethacin and digoxin are used concomitantly, serum digoxin levels should be closely monitored.

    Diuretics

    In some patients, the administration of indomethacin can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics. This response has been attributed to inhibition of renal prostaglandin synthesis.

    Indomethacin reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion. These facts should be considered when evaluating plasma renin activity in hypertensive patients.

    It has been reported that the addition of triamterene to a maintenance schedule of indomethacin resulted in reversible acute renal failure in two of four healthy volunteers. Indomethacin and triamterene should not be administered together.

    Indomethacin and potassium-sparing diuretics each may be associated with increased serum potassium levels. The potential effects of indomethacin and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently. Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by indomethacin.

    During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see WARNINGS: Renal Effects), as well as to assure diuretic efficacy.

    Lithium

    Indomethacin capsules 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady-state plasma lithium concentrations. This effect has been attributed to inhibition of prostaglandin synthesis. As a consequence, when NSAIDs and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity. (Read circulars for lithium preparations before use of such concomitant therapy.) In addition, the frequency of monitoring serum lithium concentration should be increased at the outset of such combination drug treatment.

    Methotrexate

    NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.

    NSAIDs

    The concomitant use of indomethacin with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.

    Oral anticoagulants

    Clinical studies have shown that indomethacin does not influence the hypoprothrombinemia produced by anticoagulants. However, when any additional drug, including indomethacin, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time. In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and indomethacin. Caution should be exercised when indomethacin and anticoagulants are administered concomitantly. The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.

    Probenecid

    When indomethacin is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased. Therefore, a lower total daily dosage of indomethacin may produce a satisfactory therapeutic effect. When increases in the dose of indomethacin are made, they should be made carefully and in small increments.

    DRUG/LABORATORY TEST INTERACTIONS

    False-negative results in the dexamethasone suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients

    CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY

    In an 81-week chronic oral toxicity study in the rat at doses up to 1 mg/kg/day, indomethacin had no tumorigenic effect.

    Indomethacin produced no neoplastic or hyperplastic changes related to treatment in carcinogenic studies in the rat (dosing period 73 to 110 weeks) and the mouse (dosing period 62 to 88 weeks) at doses up to 1.5 mg/kg/day.

    Indomethacin did not have any mutagenic effect in in vitro bacterial tests (Ames test and E. coli with or without metabolic activation) and a series of in vivo tests including the host-mediated assay, sex-linked recessive lethals in Drosophila, and the micronucleus test in mice.

    Indomethacin at dosage levels up to 0.5 mg/kg/day had no effect on fertility in mice in a two generation reproduction study or a two litter reproduction study in rats.

    PREGNANCY

    Teratogenic Effects. Pregnancy Category C

    Teratogenic studies were conducted in mice and rats at dosages of 0.5, 1.0, 2.0, and 4.0 mg/kg/day. Except for retarded fetal ossification at 4 mg/kg/day considered secondary to the decreased average fetal weights, no increase in fetal malformations was observed as compared with control groups. Other studies in mice reported in the literature using higher doses (5 to 15 mg/kg/day) have described maternal toxicity and death, increased fetal resorptions, and fetal malformations. Comparable studies in rodents using high doses of aspirin have shown similar maternal and fetal effects. However, animal reproduction studies are not always predictive of human response. There are no adequate and well controlled studies in pregnant women.

    Indomethacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Nonteratogenic Effects

    Because of the known effects of non-steroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly late pregnancy) should be avoided.

    The known effects of indomethacin and other drugs of this class on the human fetus during the third trimester of pregnancy include: constriction of the ductus arteriosus prenatally, tricuspid incompetence, and pulmonary hypertension; nonclosure of the ductus arteriosus postnatally which may be resistant to medical management; myocardial degenerative changes, platelet dysfunction with resultant bleeding, intracranial bleeding, renal dysfunction or failure, renal injury/dysgenesis which may result in prolonged or permanent renal failure, oligohydramnios, gastrointestinal bleeding or perforation, and increased risk of necrotizing enterocolitis.

    In rats and mice, 4.0 mg/kg/day given during the last 3 days of gestation caused a decrease in maternal weight gain and some maternal and fetal deaths. An increased incidence of neuronal necrosis in the diencephalon in the live born fetuses was observed. At 2.0 mg/kg/day, no increase in neuronal necrosis was observed as compared to the control groups. Administration of 0.5 or 4.0 mg/kg/day during the first 3 days of life did not cause an increase in neuronal necrosis at either dose level.

    LABOR AND DELIVERY

    In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred. The effects of indomethacin on labor and delivery in pregnant women are unknown.

    NURSING MOTHERS

    Indomethacin is excreted in the milk of lactating mothers. Indomethacin is not recommended for use in nursing mothers.

    PEDIATRIC USE

    Safety and effectiveness in pediatric patients 14 years of age and younger have not been established.

    Indomethacin should not be prescribed for pediatric patients 14 years of age and younger unless toxicity or lack of efficacy associated with other drugs warrants the risk.

    In experience with more than 900 pediatric patients reported in the literature or to the manufacturer who were treated with Capsules indomethacin, side effects in pediatric patients were comparable to those reported in adults. Experience in pediatric patients has been confined to the use of Capsules indomethacin.

    If a decision is made to use indomethacin for pediatric patients 2 years of age or older, such patients should be monitored closely and periodic assessment of liver function is recommended. There have been cases of hepatotoxicity reported in pediatric patients with juvenile rheumatoid arthritis, including fatalities. If indomethacin treatment is instituted, a suggested starting dose is 1 to 2 mg/kg/day given in divided doses. Maximum daily dosage should not exceed 3 mg/kg/day or 150 to 200 mg/day, whichever is less. Limited data are available to support the use of a maximum daily dosage of 4mg/kg/day or 150 to 200 mg/day, whichever is less. As symptoms subside, the total daily dosage should be reduced to the lowest level required to control symptoms, or the drug should be discontinued.

    GERIATRIC USE

    As with any NSAID, caution should be exercised in treating the elderly (65 years and older) since advancing age appears to increase the possibility of adverse reactions (see WARNINGS,Gastrointestinal Effects: Risk of Ulceration, Bleeding, and Perforation and DOSAGE AND ADMINISTRATION). Elderly patients seem to tolerate ulceration or bleeding less well than other individuals and many spontaneous reports of fatal GI events are in this population (see WARNINGS: Gastrointestinal Effects: Risk of Ulceration, Bleeding, and Perforation).

    Indomethacin may cause confusion or, rarely, psychosis (see ADVERSE REACTIONS); physicians should remain alert to the possibility of such adverse effects in the elderly.

    This drug is known to be substantially excreted by the kidney and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function (see WARNINGS: Renal Effects).

    Close
  • ADVERSE REACTIONS

    The adverse reactions for indomethacin capsules listed in the following table have been arranged into two groups: (1) incidence greater than 1%; and (2) incidence less than 1%. The incidence for group (1) was obtained from 33 double-blind controlled clinical trials reported in the literature (1,092 patients). The incidence for group (2) was based on reports in clinical trials, in the literature, and on voluntary reports since marketing. The probability of a causal relationship exists between indomethacin and these adverse reactions, some of which have been reported only rarely.
    iNCIDENCE GREATER THAN 1%
    GASTROINTESTINAL
    nausea with or without vomiting
    dyspepsia (including indigestion, heartburn and epigastric pain)
    diarrhea
    abdominal distress or pain
    constipation
    CENTRAL NEVOUS SYSTEM
    headache
    dizziness
    vertigo
    somnolence
    depression and fatigue (including malaise and listlessness)
    SPECIAL SENSES
    tinnitus
    INCIDENCE LESS THAN 1%
    GASTROINTESTINAL
    anorexia
    bloating (includes distention)
    flatulence
    peptic ulcer
    gastroenteritis
    rectal bleeding
    proctitis
    single or multiple ulcerations, including perforation and hemorrhage of the esophagus, stomach, duodenum or small and large intestines
    intestinal ulceration associated with stenosis and obstruction
    gastrointestinal bleeding without obvious ulcer formation and perforation of preexisting sigmoid lesions (diverticulum, carcinoma, etc.) development of ulcerative colitis and regional ileitis
    ulcerative stomatitis
    toxic hepatitis and jaundice (some fatal cases have been reported)
    intestinal strictures (diaphragms)
    CENTRAL NERVOUS SYSTEM
    anxiety (includes nervousness)
    muscle weakness
    involuntary muscle movements
    insomnia
    muzziness
    psychic disturbances including psychotic episodes
    mental confusion
    drowsiness
    light-headedness
    syncope
    paresthesia
    aggravation of epilepsy and parkinsonism
    depersonalization
    coma
    peripheral neuropathy
    convulsions
    dysarthria
    SPECIAL SENSES
    ocular-corneal deposits and retinal disturbances, including those of the macula, have been reported in some
    patients on prolonged therapy with indomethacin.
    blurred vision
    diplopia
    hearing disturbances, deafness
    CARDIOVASCULAR
    congestive heart failure
    hypertension
    hypotension
    tachycardia
    chest pain
    arrhythmia palpitations







    METABOLIC

    edema
    weight gain
    fluid retention
    flushing or sweating
    hyperglycemia
    glycosuria
    hyperkalemia

    INTEGUMENTARY

    pruritus
    rash; urticaria
    petechiae or ecchymosis
    exfoliative dermatitis
    erythema nodosum
    loss of hair
    Stevens-Johnson Syndrome
    erythema multiforme
    toxic epidermal necrolysis

    HEMATOLOGIC

    leukopenia
    bone marrow depression
    anemia secondary to obvious or occult gastrointestinal bleeding
    aplastic anemia
    hemolytic anemia
    agranulocytosis
    thrombocytopenic purpura
    disseminated intravascular coagulation

    HYPERSENSITIVITY

    acute anaphylaxis
    acute respiratory distress
    rapid fall in blood pressure resembling a shock-like state
    angioedema
    dyspnea
    asthma
    purpura
    angiitis
    pulmonary edema
    fever

    GENITOURINARY

    hematuria
    vaginal bleeding
    proteinuria, nephrotic syndrome, interstitial nephritis
    BUN elevation
    renal insufficiency, including renal failure

    MISCELLANEOUS

    epistaxis
    breast changes, including enlargement and tenderness, or gynecomastia

    CAUSAL RELATIONSHIP UNKNOWN

    Other reactions have been reported but occurred under circumstances where a causal relationship could not be established. However, in these rarely reported events, the possibility cannot be excluded. Therefore, these observations are being listed to serve as alerting information to physicians:

    Cardiovascular: thrombophlebitis

    Hematologic: Although there have been several reports of leukemia, the supporting information is weak.

    Genitourinary: urinary frequency

    A rare occurrence of fulminant necrotizing fasciitis, particularly in association with Group A β-hemolytic streptococcus, has been described in persons treated with non-steroidal anti-inflammatory agents, including indomethacin, sometimes with fatal outcome (see also PRECAUTIONS: General).

    Close
  • OVERDOSAGE

    The following symptoms may be observed following overdosage: nausea, vomiting, intense headache, dizziness, mental confusion, disorientation, or lethargy. There have been reports of paresthesias, numbness and convulsions.

    Treatment is symptomatic and supportive. The stomach should be emptied as quickly as possible if the ingestion is recent. If vomiting has not occurred spontaneously, the patient should be induced to vomit with syrup of ipecac. If the patient is unable to vomit, gastric lavage should be performed. Once the stomach has been emptied, 25 g or 50 g of activated charcoal may be given. Depending on the condition of the patient, close medical observation and nursing care may be required. The patient should be followed for several days because gastrointestinal ulceration and hemorrhage have been reported as adverse reactions of indomethacin. Use of antacids may be helpful.

    The oral LD50 of indomethacin in mice and rats (based on 14 day mortality response) was 50 and 12 mg/kg, respectively

    Close
  • DOSAGE AND ADMINISTRATION

    Carefully consider the potential benefits and risks of indomethacin and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).

    After observing the response to initial therapy with indomethacin, the dose and frequency should be adjusted to suit an individual patient's needs.

    Indomethacin is available as 75 mg capsules.

    Adverse reactions appear to correlate with the size of the dose of indomethacin in most patients but not all. Therefore, every effort should be made to determine the smallest effective dosage for the individual patient

    Pediatric Use

    Indomethacin ordinarily should not be prescribed for pediatric patients 14 years of age and under (see WARNINGS).

    Adult Use

    Dosage Recommendations for Active Stages of the Following:

    1. Moderate to severe rheumatoid arthritis including acute flares of chronic disease; moderate to severe ankylosing spondylitis; and moderate to severe osteoarthritis.
     
    Suggested Dosage: Indomethacin capsules 75 mg b.i.d. or t.i.d. If this is well tolerated, increase the daily dosage by 75 mg, if required by continuing symptoms, at weekly intervals until a satisfactory response is obtained or until a total daily dose of 150 mg to 200 mg is reached. DOSES ABOVE THIS AMOUNT GENERALLY DO NOT INCREASE THE EFFECTIVENESS OF THE DRUG.

    In patients who have persistent night pain and/or morning stiffness, the giving of a large portion, up to a maximum of 100 mg, of the total daily dose at bedtime may be helpful in affording relief. The total daily dose should not exceed 200 mg. In acute flares of chronic rheumatoid arthritis, it may be necessary to increase the dosage by 75 mg daily.

    If minor adverse effects develop as the dosage is increased, reduce the dosage rapidly to a tolerated dose and OBSERVE THE PATIENT CLOSELY.

    If severe adverse reactions occur, STOP THE DRUG. After the acute phase of the disease is under control, an attempt to reduce the daily dose should be made repeatedly until the patient is receiving the smallest effective dose or the drug is discontinued.

    Careful instructions to, and observations of, the individual patient are essential to the prevention of serious, irreversible, including fatal, adverse reactions.

    As advancing years appear to increase the possibility of adverse reactions, indomethacin should be used with greater care in the elderly (see PRECAUTIONS: Geriatric Use).

    2. Acute painful shoulder (bursitis and/or tendinitis).
     
    Initial Dose: 75 mg to 150 mg daily in 3 or 4 divided doses. The drug should be discontinued after the signs and symptoms of inflammation have been controlled for several days. The usual course of therapy is 7 to 14 days.
      3. Acute gouty arthritis.
     
    Suggested Dosage: Indomethacin capsules 75 mg t.i.d. until pain is tolerable. The dose should then be rapidly reduced to complete cessation of the drug. Definite relief of pain has been reported within 2 to 4 hours. Tenderness and heat usually subside in 24 to 36 hours, and swelling gradually disappears in 3 to 5 days
    Close
  • Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

    Please ask your Pharmacist for a complete medication guide for this prescription.
    Close
  • HOW SUPPLIED

    Manufactured by KVK-Tech Inc.Indomethacin Extended-release Capsules USP 75 mg are supplied as yellow opaque cap,
    natural body with black imprint K-16 on both cap and body, filled with white pellets.

     Available as follows:

    NDC 12634-160-91 Blister Pack UD 1's
    NDC 12634-160-54 Blister Pack Card of 14
    NDC 12634-160-55 Blister Pack Card of 15
    NDC 12634-160-57 Blister Pack Card of 20
    NDC 12634-160-25 Blister Pack Card of 25
    NDC 12634-160-59 Blister Pack Card of 30
    NDC 12634-160-97 Bottle of 7
    NDC 12634-160-00 Bottle of 10
    NDC 12634-160-84 Bottle of 14
    NDC 12634-160-85 Bottle of 15
    NDC 12634-160-80 Bottle of 20
    NDC 12634-160-79 Bottle of 25
    NDC 12634-160-71 Bottle of 30
    NDC 12634-160-60 Bottle of 60

    Manufactured by Epic Pharm LLC for Sandoz INC. Indomethacin extended-release capsules 75 mg is supplied as green and clear capsules, imprinted E 720.

    Available as follows:

    NDC 12634-838-91 Blister Pack UD 1's
    NDC 12634-838-66 Blister Pack Card of 6
    NDC 12634-838-67 Blister Pack Card of 7
    NDC 12634-838-61 Blister Pack Card of 10
    NDC 12634-838-54 Blister Pack Card of 14
    NDC 12634-838-55 Blister Pack Card of 15
    NDC 12634-838-57 Blister Pack Card of 20
    NDC 12634-838-59 Blister Pack Card of 30
    NDC 12634-838-95 Bottle of 5
    NDC 12634-838-97 Bottle of 7
    NDC 12634-838-00 Bottle of 10
    NDC 12634-838-84 Bottle of 14
    NDC 12634-838-85 Bottle of 15
    NDC 12634-838-80 Bottle of 20
    NDC 12634-838-79 Bottle of 25
    NDC 12634-838-71 Bottle of 30
    NDC 12634-838-50 Bottle of 50
    NDC 12634-838-60 Bottle of 60
    NDC 12634-838-90 Bottle of 90



    Close
  • STORAGE AND DISPENSING

    Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]
    Protect from light.

    Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
    PHARMACIST: Dispense a Medication Guide with each prescription

    Close
  • PACKAGE LABEL AND PRINCIPAL DISPLAY PANEL ADDITIONAL LABELS UPON REQUEST

    NDC 12634-160-71 30 CAPSULES
    Each Capsule Contains:
    Indomethacin E-R 75MG
    RX Only
    Usual Adult Dosage:
    See insert for full prescribing information. Dispense
    with a Patient Medication Guide.
    Keep this and all Medication out of the reach of Children.
    Manufactures by:
    Epic Pharma LLC
    For Sandoz, Inc.
    NDC 0185-0720-60
    Repackaged and Distributed by:
    Apotheca, Inc.
    Phoenix, AZ. 85006


    image of label











    Close
  • INGREDIENTS AND APPEARANCE
    INDOMETHACIN ER 
    indomethacin capsule
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:12634-160(NDC:10702-016)
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    INDOMETHACIN (INDOMETHACIN) INDOMETHACIN 75 mg
    Inactive Ingredients
    Ingredient Name Strength
    D&C YELLOW NO. 10  
    GELATIN  
    MANNITOL  
    POVIDONE  
    SUCROSE  
    TALC  
    TITANIUM DIOXIDE  
    Product Characteristics
    Color yellow (YELLOW OPAQUE) Score no score
    Shape CAPSULE (CAPSULE) Size 15mm
    Flavor Imprint Code K;16
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:12634-160-91 1 in 1 BLISTER PACK
    2 NDC:12634-160-54 14 in 1 BLISTER PACK
    3 NDC:12634-160-55 15 in 1 BLISTER PACK
    4 NDC:12634-160-57 20 in 1 BLISTER PACK
    5 NDC:12634-160-25 25 in 1 BLISTER PACK
    6 NDC:12634-160-59 30 in 1 BLISTER PACK
    7 NDC:12634-160-97 7 in 1 BOTTLE, PLASTIC
    8 NDC:12634-160-00 10 in 1 BOTTLE, PLASTIC
    9 NDC:12634-160-84 14 in 1 BOTTLE, PLASTIC
    10 NDC:12634-160-85 15 in 1 BOTTLE, PLASTIC
    11 NDC:12634-160-80 20 in 1 BOTTLE, PLASTIC
    12 NDC:12634-160-79 25 in 1 BOTTLE, PLASTIC
    13 NDC:12634-160-71 30 in 1 BOTTLE, PLASTIC
    14 NDC:12634-160-60 60 in 1 BOTTLE, PLASTIC
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA079175 03/04/2010
    INDOMETHACIN ER 
    indomethacin capsule
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:12634-838(NDC:0185-0720)
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    INDOMETHACIN (INDOMETHACIN) INDOMETHACIN 75 mg
    Inactive Ingredients
    Ingredient Name Strength
    D&C YELLOW NO. 10  
    FD&C BLUE NO. 1  
    FD&C BLUE NO. 2  
    FD&C RED NO. 40  
    FD&C GREEN NO. 3  
    ETHYLCELLULOSE  
    GELATIN  
    LACTOSE MONOHYDRATE  
    POVIDONE  
    SILICON DIOXIDE  
    SODIUM LAURETH SULFATE  
    STARCH, CORN  
    SUCROSE  
    TALC  
    TITANIUM DIOXIDE  
    Product Characteristics
    Color green (green clear) Score no score
    Shape CAPSULE (capsule) Size 17mm
    Flavor Imprint Code E;720
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:12634-838-91 1 in 1 BLISTER PACK
    2 NDC:12634-838-66 6 in 1 BLISTER PACK
    3 NDC:12634-838-67 7 in 1 BLISTER PACK
    4 NDC:12634-838-61 10 in 1 BLISTER PACK
    5 NDC:12634-838-54 14 in 1 BLISTER PACK
    6 NDC:12634-838-55 15 in 1 BLISTER PACK
    7 NDC:12634-838-57 20 in 1 BLISTER PACK
    8 NDC:12634-838-59 30 in 1 BLISTER PACK
    9 NDC:12634-838-95 5 in 1 BOTTLE
    10 NDC:12634-838-97 7 in 1 BOTTLE
    11 NDC:12634-838-00 10 in 1 BOTTLE
    12 NDC:12634-838-84 14 in 1 BOTTLE
    13 NDC:12634-838-85 15 in 1 BOTTLE
    14 NDC:12634-838-80 20 in 1 BOTTLE
    15 NDC:12634-838-79 25 in 1 BOTTLE
    16 NDC:12634-838-71 30 in 1 BOTTLE
    17 NDC:12634-838-50 50 in 1 BOTTLE
    18 NDC:12634-838-60 60 in 1 BOTTLE
    19 NDC:12634-838-90 90 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA074464 05/02/2006
    Labeler - Apotheca, Inc. (051457844)
    Establishment
    Name Address ID/FEI Business Operations
    Apotheca, Inc. 051457844 relabel, repack
    Close